Vithas Nears GenesisCare Spain Oncology Deal

Vithas, Spain's second-largest hospital operator, is reportedly in advanced discussions to acquire the Spanish operations of GenesisCare, an Australian oncology specialist. This strategic move would significantly bolster Vithas's cancer treatment capabilities by integrating 18 dedicated oncology centers across Spain into its existing network.

The transaction, valued in the range of €40 million to €50 million, represents a key expansion for Vithas, which is wholly owned by the Gallardo family, the founders of pharmaceutical giant Almirall. The acquisition aligns with Vithas's strategy to enhance its specialized service offerings in a growing healthcare market.

GenesisCare's Spanish division has been on the market for several months, with KPMG advising on the sale. Following a significant restructuring in 2024, the group's international subsidiaries, including the Spanish entity, now operate independently. Key stakeholders in GenesisCare post-restructuring include Oaktree Capital Management, a prominent alternative investment firm, alongside other debt-to-equity converters such as Avenue Capital, Bain Capital, and Canyon Partners. The parent company is backed by the Canadian financial powerhouse Brookfield.

Vithas emerged as the preferred bidder, surpassing interest from entities like Mercurius Health Group, which is affiliated with Alliance Medical Group. This competitive process underscores the strategic value of GenesisCare's Spanish oncology footprint. The Spanish healthcare sector, particularly specialized services like oncology, continues to attract significant investment, driven by an aging population and increasing demand for advanced medical treatments.

With a robust presence across 14 Spanish provinces, Vithas currently operates 22 hospitals and 40 medical centers, boasting over 1,800 beds and employing approximately 14,500 professionals. The group reported revenues of €796 million in 2025, reflecting a steady growth trajectory. The integration of GenesisCare's specialized centers is expected to further solidify Vithas's market position and enhance its comprehensive care model.

This acquisition is particularly noteworthy within the context of the European healthcare M&A market, which has seen a surge in consolidation as providers seek economies of scale and enhanced service portfolios. The oncology segment, specifically, is a critical area of focus, given the rising incidence of cancer globally and the continuous advancements in treatment modalities like radiotherapy, which is GenesisCare's core expertise.